AM I NEXT? NO LOVE AT XELLIA PHARMACEUTICALS USA

Buffalo Grove, Illinois-based Xellia Pharmaceuticals USA, a multinational pharmaceutical and life sciences company, has announced a divestiture of assets, including its 24-acre Bedford, Ohio manufacturing facility.

The reduction in force will impact 247 employees, including 214 employees at its Bedford, Ohio facility. Layoffs, including microbiologists, analytical chemists, inspection, packaging operators, and aseptic operators, will be phased from August 2024 through the end of December 2024.

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something bad hasn't happened yet doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?

AM I NEXT? NO LOVE AT BAYER AG

Leverkusen, Germany-based Bayer, a multinational conglomerate specializing in pharmaceuticals, biotechnology, agricultural chemicals, and consumer healthcare products, has announced a major reduction in force since introducing its new "Dynamic Shared Ownership" operating model designed to “reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes.”

The company had disclosed it made 1,500 job cuts in Q1, the first three months of 2024, with two-thirds being management roles. The company's has been reduced from fourteen positions to eight positions.

Additional layoffs are expected with "layoffs to be completed by the end of 2025 at the latest. We are adjusting our U.S. structure resulting in some positions being eliminated or redesigned, and a few new roles being created.”

CEO Bill Anderson noted, “Our senior leadership circle is already considerably smaller than it was a year ago. We’re consolidating roles, designing teams for more impact, and taking out layers. We’ve said from the beginning, our focus really isn’t on a head count number. Our focus is really relentless on making sure that every job in the company is oriented around the mission. That’s one of the reasons this is very different from a typical restructuring exercise, where the management decides what’s the number and then just sort of dispenses targets. We haven’t done that, and we’re not going to do that. People are just amazed at how much more they can get done when they have the authority with their colleagues to make the decisions and move.”

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something bad hasn't happened yet doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?

AM I NEXT? NO LOVE AT AMYLYX

Cambridge, Massachsetts-based Amylyx, a biopharmaceutical company specializing in therapeutics for treating amyotrophic lateral sclerosis, has announced a major reduction in force following the voluntary withdrawal of Relyvrio from the marketplace due to its failure in a confirmatory clinical trial.

The reduction will impact up to 70% of the company's workforce or approximately 274 employees.

According to an SEC filing...

"On March 8, 2024, the Company announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO in the U.S., ALBRIOZA™ in Canada) in people living with amyotrophic lateral sclerosis (ALS). PHOENIX did not meet its primary endpoint of reaching statistical significance (p=0.667) as measured by change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score at Week 48, nor was there statistical significance seen in secondary endpoints."

"On April 3, 2024, the board of directors of Amylyx Pharmaceuticals, Inc. (the “Company”) approved a restructuring plan designed to focus the Company’s resources on key clinical and preclinical programs (the “Restructuring Plan”). The Restructuring Plan includes a reduction in force which is expected to reduce the Company’s workforce by approximately 70% and a decrease in external financial commitments outside of its priority areas. The Company expects to substantially complete the Restructuring Plan by the end of the third quarter of 2024. As part of this Restructuring Plan, the Company expects to incur severance and severance-related charges of approximately $19 million."

"The Company is also evaluating its inventory purchase commitments and the impact its Restructuring Plan will have on inventory obsolescence. The Company may also incur other charges or cash expenditures not currently contemplated or that cannot be currently estimated due to events that may occur as a result of, or associated with, the Restructuring Plan."

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something bad hasn't happened yet doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?